Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
3.910 ^USD	-3.46%		-9.07%	-28.49%

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-22	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE

Transcript : Bolt Biotherapeutics, Inc. - Special Call

Published on 05/12/2025 at 01:00 pm BST - Modified on 05/12/2025 at 10:30 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good afternoon, and welcome to the Bolt Biotherapeutics BDC-3042 Phase I dose-escalation study and clinical programs update conference call. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Bolt Biotherapeutics, Inc.

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-22	Alert wrongly tagged to Bolt Biotherapeutics Inc withdrawn	RE
01-15	Bolt appoints Olta Andoni as SVP of legal and people to support platform expansion across checkout, identity, and payments	RE
11-12	Bolt Biotherapeutics Q3 collaboration revenue doubles	RE
11-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
02/10/25	Bolt Biotherapeutics, Inc. Announces Reduction of its Current Workforce by Approximately 20 Employees, or Approximately 50% of its Workforce	CI
02/10/25	Bolt Biotherapeutics, Inc. Provides Update on Ongoing Phase 1 Dose Escalation Study of BDC-4182	CI
02/10/25	Washington Shutdown Continues as US Equity Futures Trade Mixed Ahead of Opening Bell	MT
02/10/25	Top Premarket Decliners	MT
01/10/25	Bolt Biotherapeutics to Cut Workforce by 50%; Cancer Drug Trial Data Expected in Q3 of 2026	MT
01/10/25	Bolt Biotherapeutics Provides Update on BDC-4182	CI
14/08/25	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
06/06/25	Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025	RE
12/05/25	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/05/25	Bolt Biotherapeutics, Inc. - Special Call